Tremelimumab
Information
- Drug Name
- Tremelimumab
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In this phase II trial (metastatic setting), anti-... | CTLA4 | CTLA4 UNKNOWN | Resitance or Non-Reponse | true | MMMP | detail |
| Phase II trial. Eight (10%) of 84 response-assessa... | CTLA4 | CTLA4 UNKNOWN | Sensitivity | true | MMMP | detail |
| Response rate: 14% | CTLA4 | CTLA4 UNKNOWN | Sensitivity | true | MMMP | detail |
| Phase III RCT of tremelimumab versus physician cho... | CTLA4 | CTLA4 UNKNOWN | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03994393 | Active, not recruiting | Phase 2 | Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. | October 23, 2018 | January 31, 2024 |
| NCT02888743 | Active, not recruiting | Phase 2 | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | August 14, 2017 | January 2, 2025 |
| NCT03959293 | Active, not recruiting | Phase 2 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | July 17, 2019 | September 27, 2023 |
| NCT02953457 | Active, not recruiting | Phase 2 | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | June 29, 2017 | October 15, 2024 |
| NCT03923270 | Active, not recruiting | Phase 1 | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | June 6, 2019 | June 1, 2024 |
| NCT02879318 | Active, not recruiting | Phase 2 | Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma | November 7, 2016 | December 31, 2024 |
| NCT02453282 | Active, not recruiting | Phase 3 | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) | July 21, 2015 | December 31, 2024 |
| NCT04395079 | Active, not recruiting | Phase 2 | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | August 7, 2020 | June 1, 2025 |
| NCT03871036 | Active, not recruiting | Phase 1/Phase 2 | Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | May 1, 2019 | January 31, 2025 |
| NCT03043872 | Active, not recruiting | Phase 3 | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | March 27, 2017 | December 31, 2024 |
| NCT03046862 | Active, not recruiting | Phase 2 | Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer | February 25, 2017 | December 31, 2024 |
| NCT03057106 | Active, not recruiting | Phase 2 | Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | March 28, 2017 | December 31, 2024 |
| NCT03753919 | Active, not recruiting | Phase 2 | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial | April 2, 2019 | December 2024 |
| NCT03704480 | Active, not recruiting | Phase 2 | Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | November 9, 2018 | December 31, 2024 |
| NCT04156087 | Active, not recruiting | Phase 2 | Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer | May 9, 2020 | December 31, 2023 |
| NCT02571725 | Active, not recruiting | Phase 1/Phase 2 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | February 23, 2016 | July 15, 2027 |
| NCT02516241 | Active, not recruiting | Phase 3 | Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | November 2, 2015 | December 30, 2024 |
| NCT02519348 | Active, not recruiting | Phase 2 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | October 19, 2015 | March 31, 2025 |
| NCT04159974 | Active, not recruiting | Phase 2 | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus | September 30, 2019 | June 2024 |
| NCT03703297 | Active, not recruiting | Phase 3 | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | September 27, 2018 | September 5, 2024 |
| NCT02788773 | Active, not recruiting | Phase 2 | Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer | December 15, 2016 | June 30, 2024 |
| NCT05239169 | Active, not recruiting | Phase 2 | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | May 23, 2022 | June 30, 2025 |
| NCT03682068 | Active, not recruiting | Phase 3 | Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer | September 27, 2018 | June 30, 2025 |
| NCT03158064 | Active, not recruiting | Phase 2 | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | May 15, 2017 | November 2024 |
| NCT03164616 | Active, not recruiting | Phase 3 | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). | June 1, 2017 | December 31, 2026 |
| NCT02812420 | Active, not recruiting | Early Phase 1 | Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery | March 7, 2017 | December 31, 2024 |
| NCT02815995 | Active, not recruiting | Phase 2 | Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes | August 16, 2016 | December 27, 2025 |
| NCT02819596 | Active, not recruiting | Phase 2 | MEDI4736 Combinations in Metastatic Renal Cell Carcinoma | January 2017 | March 2023 |
| NCT03212469 | Active, not recruiting | Phase 1/Phase 2 | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer | June 20, 2017 | December 2024 |
| NCT03601455 | Active, not recruiting | Phase 2 | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | October 26, 2018 | January 31, 2026 |
| NCT03237377 | Active, not recruiting | Phase 2 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | December 12, 2017 | May 28, 2024 |
| NCT03581487 | Active, not recruiting | Phase 1/Phase 2 | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | April 1, 2019 | December 31, 2025 |
| NCT03557918 | Active, not recruiting | Phase 2 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | November 12, 2018 | April 2023 |
| NCT03283605 | Active, not recruiting | Phase 1/Phase 2 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | July 17, 2018 | December 2023 |
| NCT03549715 | Active, not recruiting | Phase 1/Phase 2 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma | December 6, 2018 | September 2025 |
| NCT03539822 | Active, not recruiting | Phase 1/Phase 2 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies | October 22, 2018 | November 30, 2027 |
| NCT03509012 | Active, not recruiting | Phase 1 | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors | May 2, 2018 | December 31, 2024 |
| NCT01843374 | Active, not recruiting | Phase 2 | Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma | May 17, 2013 | December 31, 2024 |
| NCT03410615 | Active, not recruiting | Phase 2 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | May 28, 2018 | July 31, 2026 |
| NCT04034927 | Active, not recruiting | Phase 2 | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | December 4, 2019 | September 21, 2024 |
| NCT02537418 | Active, not recruiting | Phase 1 | Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens | October 16, 2015 | December 31, 2024 |
| NCT05345678 | Approved for marketing | Himalaya Early Access Program | |||
| NCT03101475 | Completed | Phase 2 | Synergism of Immunomodulation and Tumor Ablation | November 23, 2018 | February 23, 2022 |
| NCT03122496 | Completed | Phase 1 | Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer | April 25, 2017 | June 3, 2022 |
| NCT03122509 | Completed | Phase 2 | A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer | April 24, 2017 | April 28, 2021 |
| NCT03132467 | Completed | Early Phase 1 | Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer | June 13, 2017 | May 20, 2024 |
| NCT03144778 | Completed | Phase 1 | Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer | July 12, 2017 | March 15, 2021 |
| NCT03164772 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC | December 20, 2017 | October 29, 2021 |
| NCT03204812 | Completed | Phase 2 | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer | July 14, 2017 | April 13, 2021 |
| NCT03206073 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | December 7, 2017 | June 30, 2022 |
| NCT03373760 | Completed | Phase 2 | Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | November 30, 2017 | March 29, 2022 |
| NCT03452332 | Completed | Phase 1 | Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers | July 18, 2018 | August 11, 2023 |
| NCT03472274 | Completed | Phase 2 | Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) | October 25, 2018 | April 12, 2023 |
| NCT03473574 | Completed | Phase 2 | Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients | May 2, 2018 | March 15, 2022 |
| NCT02701400 | Completed | Phase 2 | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | April 14, 2016 | August 7, 2020 |
| NCT01853618 | Completed | Phase 1/Phase 2 | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | May 2, 2013 | June 7, 2017 |
| NCT01938612 | Completed | Phase 1 | A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours | September 12, 2013 | November 25, 2020 |
| NCT01975831 | Completed | Phase 1 | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | December 19, 2013 | July 2, 2021 |
| NCT02000947 | Completed | Phase 1 | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer | October 25, 2013 | September 17, 2019 |
| NCT02040064 | Completed | Phase 1 | Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients | January 2014 | March 2016 |
| NCT02117219 | Completed | Phase 1 | Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome | May 20, 2014 | April 30, 2019 |
| NCT02141347 | Completed | Phase 1 | Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma | May 22, 2014 | January 27, 2017 |
| NCT02141542 | Completed | Phase 1 | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | May 2014 | September 23, 2020 |
| NCT02154490 | Completed | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | July 8, 2014 | April 15, 2022 | |
| NCT02179671 | Completed | Phase 2 | Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | July 25, 2014 | June 11, 2016 |
| NCT02261220 | Completed | Phase 1 | A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | October 13, 2014 | January 27, 2020 |
| NCT02262741 | Completed | Phase 1 | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer | October 15, 2014 | September 21, 2017 |
| NCT02301130 | Completed | Phase 1 | Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors | November 26, 2014 | March 5, 2018 |
| NCT02311361 | Completed | Phase 1/Phase 2 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | March 25, 2015 | December 31, 2020 |
| NCT02319044 | Completed | Phase 2 | Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | April 15, 2015 | July 6, 2020 |
| NCT02340975 | Completed | Phase 1/Phase 2 | A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | March 31, 2015 | April 29, 2019 |
| NCT02535078 | Completed | Phase 1/Phase 2 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | November 2015 | June 19, 2023 |
| NCT02536794 | Completed | Phase 2 | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer | January 14, 2016 | January 22, 2021 |
| NCT02549651 | Completed | Phase 1 | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) | July 13, 2016 | February 4, 2019 |
| NCT02551159 | Completed | Phase 3 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer | October 15, 2015 | May 21, 2021 |
| NCT02563925 | Completed | N/A | Brain Irradiation and Tremelimumab in Metastatic Breast Cancer | September 18, 2015 | July 14, 2021 |
| NCT02586987 | Completed | Phase 1 | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours | December 28, 2015 | September 20, 2019 |
| NCT02592551 | Completed | Phase 2 | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | May 11, 2016 | September 1, 2022 |
| NCT02626130 | Completed | Early Phase 1 | Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer | March 30, 2016 | June 20, 2022 |
| NCT02639026 | Completed | Phase 1 | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | January 26, 2016 | June 27, 2023 |
| NCT02643303 | Completed | Phase 1/Phase 2 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | December 28, 2016 | February 23, 2022 |
| NCT02658214 | Completed | Phase 1 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | April 28, 2016 | November 14, 2019 |
| NCT01103635 | Completed | Phase 1 | Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | February 2010 | May 2, 2016 |
| NCT02705482 | Completed | Phase 1 | A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors | March 30, 2016 | August 7, 2019 |
| NCT02718911 | Completed | Phase 1 | A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors | June 16, 2016 | December 14, 2018 |
| NCT02735239 | Completed | Phase 1/Phase 2 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | June 24, 2016 | June 16, 2022 |
| NCT02754856 | Completed | Phase 1 | Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery | July 28, 2016 | January 30, 2023 |
| NCT02762006 | Completed | Phase 1 | Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | December 20, 2016 | November 6, 2020 |
| NCT02794883 | Completed | Phase 2 | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | November 1, 2016 | June 17, 2020 |
| NCT02821754 | Completed | Phase 2 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | July 5, 2016 | December 31, 2022 |
| NCT02870920 | Completed | Phase 2 | Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer | October 12, 2016 | June 7, 2022 |
| NCT03005002 | Completed | Phase 1 | Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver | June 28, 2017 | November 26, 2019 |
| NCT03007407 | Completed | Phase 2 | Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | July 31, 2017 | August 9, 2019 |
| NCT03015129 | Completed | Phase 2 | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | January 2017 | December 30, 2022 |
| NCT03085849 | Completed | Phase 1 | SGI-110 Plus Durvalumab/Tremelimumab in SCLC | December 15, 2017 | November 26, 2018 |
| NCT03095274 | Completed | Phase 2 | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin | April 11, 2017 | May 23, 2022 |
| NCT03624231 | Completed | Phase 2 | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC | August 15, 2018 | August 17, 2023 |
| NCT03693612 | Completed | Phase 1/Phase 2 | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | November 26, 2018 | September 16, 2021 |
| NCT04274816 | Completed | Phase 1 | Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | July 10, 2012 | February 27, 2014 |
| NCT04522544 | Recruiting | Phase 2 | Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC | December 15, 2020 | September 30, 2025 |
| NCT03288532 | Recruiting | Phase 3 | Renal Adjuvant MultiPle Arm Randomised Trial | July 19, 2018 | December 1, 2034 |
| NCT03482102 | Recruiting | Phase 2 | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | May 14, 2018 | October 2026 |
| NCT06008093 | Recruiting | Phase 3 | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients | April 4, 2024 | March 12, 2031 |
| NCT05883644 | Recruiting | Phase 3 | Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) | June 27, 2023 | December 30, 2025 |
| NCT05809869 | Recruiting | Phase 2 | Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma | February 15, 2023 | June 30, 2026 |
| NCT03606967 | Recruiting | Phase 2 | Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | April 13, 2021 | December 31, 2024 |
| NCT05701488 | Recruiting | Phase 1 | SIRT With Tremelimumab and Durvalumab for Resectable HCC | April 21, 2023 | October 1, 2025 |
| NCT06017297 | Recruiting | Phase 2 | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma | June 2024 | November 2026 |
| NCT05557838 | Recruiting | Phase 3 | Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma | February 22, 2023 | March 31, 2025 |
| NCT06058663 | Recruiting | Phase 1 | Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma | June 6, 2024 | November 30, 2025 |
| NCT05451043 | Recruiting | Phase 2 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | July 5, 2023 | October 1, 2028 |
| NCT05440864 | Recruiting | Phase 2 | Durvalumab and Tremelimumab in Resectable HCC | October 26, 2023 | November 2026 |
| NCT05380713 | Recruiting | Phase 2 | ......SMARTEST Trial...... | May 3, 2022 | October 30, 2028 |
| NCT03317158 | Recruiting | Phase 1/Phase 2 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | November 21, 2017 | December 31, 2025 |
| NCT03847649 | Recruiting | Phase 2 | A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies | March 9, 2020 | April 30, 2031 |
| NCT03026062 | Recruiting | Phase 2 | Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | May 18, 2017 | December 15, 2024 |
| NCT02962063 | Recruiting | Phase 1/Phase 2 | Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer | November 2016 | November 2024 |
| NCT03937830 | Recruiting | Phase 2 | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | March 10, 2021 | December 31, 2025 |
| NCT02938793 | Recruiting | Phase 2 | Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors | December 1, 2016 | June 1, 2027 |
| NCT03965468 | Recruiting | Phase 2 | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | November 19, 2019 | December 2026 |
| NCT03975114 | Recruiting | Phase 2 | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) | December 20, 2018 | June 30, 2024 |
| NCT05301842 | Recruiting | Phase 3 | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC | March 28, 2022 | February 26, 2027 |
| NCT05027425 | Recruiting | Phase 2 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | December 7, 2021 | December 7, 2030 |
| NCT05000710 | Recruiting | Phase 2 | Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy | December 9, 2021 | December 2026 |
| NCT04988945 | Recruiting | Phase 2 | TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma | December 1, 2020 | December 1, 2026 |
| NCT04107168 | Recruiting | Microbiome Immunotherapy Toxicity and Response Evaluation | July 8, 2020 | July 8, 2025 | |
| NCT04960709 | Recruiting | Phase 3 | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin | August 5, 2021 | September 8, 2028 |
| NCT04817826 | Recruiting | Phase 2 | TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. | April 1, 2021 | April 30, 2025 |
| NCT04238637 | Recruiting | Phase 2 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | November 1, 2019 | December 2025 |
| NCT06109272 | Recruiting | Phase 2/Phase 3 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | January 11, 2024 | September 6, 2030 |
| NCT04605731 | Recruiting | Phase 1 | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | August 3, 2021 | December 31, 2024 |
| NCT04585490 | Recruiting | Phase 3 | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | August 25, 2021 | April 1, 2028 |
| NCT04430452 | Recruiting | Phase 2 | Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition | February 4, 2022 | February 28, 2027 |
| NCT04499053 | Recruiting | Phase 2 | Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer | December 9, 2020 | December 2024 |
| NCT03075527 | Suspended | Phase 2 | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | April 10, 2017 | September 30, 2024 |
| NCT02485990 | Terminated | Phase 1 | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | January 8, 2016 | March 5, 2020 |
| NCT02616185 | Terminated | Phase 1 | A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) | December 30, 2015 | February 23, 2021 |
| NCT02716805 | Terminated | Phase 1 | Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant | December 13, 2016 | February 16, 2018 |
| NCT03081923 | Terminated | Phase 2 | Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors | February 1, 2017 | December 6, 2019 |
| NCT03618134 | Terminated | Phase 1/Phase 2 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | October 4, 2018 | June 30, 2023 |
| NCT03234153 | Terminated | Phase 2 | Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin | July 15, 2018 | May 18, 2020 |
| NCT03275597 | Terminated | Phase 1 | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | February 20, 2018 | July 1, 2020 |
| NCT03277482 | Terminated | Phase 1 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | June 1, 2018 | July 15, 2022 |
| NCT03522584 | Terminated | Phase 1/Phase 2 | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | May 17, 2018 | January 19, 2022 |
| NCT04287894 | Unknown status | Phase 1 | Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment | December 28, 2018 | January 1, 2021 |
| NCT01649024 | Unknown status | Phase 2 | A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma | May 2009 | June 2013 |
| NCT03702179 | Unknown status | Phase 2 | Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach | November 19, 2018 | December 2022 |
| NCT02879162 | Unknown status | Phase 2 | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | October 19, 2016 | December 31, 2022 |
| NCT01655888 | Unknown status | Phase 2 | The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma | July 2012 | January 2015 |
| NCT03150836 | Withdrawn | Phase 2 | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer | October 1, 2017 | September 1, 2024 |
| NCT03598816 | Withdrawn | Phase 2 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma | August 31, 2020 | May 31, 2024 |
| NCT04073160 | Withdrawn | Phase 1 | TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer | June 2020 | January 2026 |
| NCT02868632 | Withdrawn | Phase 1 | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | August 7, 2016 | March 4, 2019 |
| NCT05120622 | Withdrawn | Phase 1/Phase 2 | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer | September 1, 2021 | May 1, 2022 |
| NCT03982173 | Withdrawn | Phase 2 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors | September 2020 | December 5, 2024 |
| NCT03319316 | Withdrawn | Phase 2 | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) | November 1, 2018 | November 2022 |
| NCT03130764 | Withdrawn | Phase 2 | Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC | March 2017 | November 30, 2017 |
| NCT04625699 | Withdrawn | Phase 2 | Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment | December 2022 | December 2023 |